PCPA Webinar: MBS item numbers for chemotherapy services

PCPA Webinar: MBS item numbers for chemotherapy services

 

Webinar Oct 2020 banner

MBS item numbers for chemotherapy services – changes to be implemented on 1 November 2020

This event has now ended, to view a recording of this webinar please click here to log into the member's only area. 

Date: Tuesday 20th October, 2020
Time: 8:00pm - 9:00pm (AEDT)

On 1 November 2020, the structure to chemotherapeutic procedures listed on the Medicare Benefits Schedule (MBS) will change. These changes result from the recommendations of the MBS Review Taskforce Oncology Clinical Committee Report 2018 (publicly available at www.health.gov.au), and progressive liaison between the Department of Health and peak professional bodies (including PCPA, MOGA and HSANZ). 

Click on below image to view a recordingof the webinar:

 

In this webinar we covered:

1. The new, simplified MBS structure for chemotherapy procedures

  • All time-based item numbers to be replaced by single item number 13950 for administration of parenteral anti-neoplastic therapy, by or on behalf of a specialist or consultant physician.
  • Deletion of item number 13945
  • Modification to item number 14221

2. Impact to practices for oversight and management of therapeutic agents

3. Legal aspects of the MBS and principles of billing for cancer clinicians 

PCPA is hosting this webinar as part of our ongoing service to members to ensure you have a complete understanding of MBS billing requirements, so that Medicare benefits can be complied with and accessed both appropriately and accurately. 

*Disclaimer: The material presented in this webinar was correct on 20 October 2020. Medicare law changes constantly and you should therefore seek independent legal advice before relying on specific legal content in this presentation after that date.
 
The PCPA leadership will continue to seek further clarity on the items that were not addressed during the webinar.
 

Guest speakers:

dr Primrose

Dr John Primrose - Principal Medical Advisor, Medical Benefits Division, Department of Health, Australian Government

Dr Primrose trained and practised as a radiation oncologist. He has worked in the Department of Health since 1990, as advisor to both the Pharmaceutical Benefits Scheme and Medicare. He has a particular interest in clinical trials, health technology assessment and the promotion of quality healthcare.  

Margaret

Margaret Faux – Founder & Chief Executive Officer

A passion for learning and working with people has steered Margaret through a rich and diverse working life. Her interest in the medical professions has endured throughout this journey and her dedication to the health sector lies at the heart of Synapse Medical Services.

Margaret is a Solicitor specialising in Medicare and Health Insurance Law, a Registered Nurse and is currently completing a doctoral project at the University of Technology Sydney on Medicare claiming and compliance. Margaret worked for over a decade as a Registered Nurse in various public and private hospital settings and has over 30 years’ experience in the operation of Medicare and Australia’s health financing arrangements.

Margaret has an adjunct appointment at Southern Cross University working in medical billing and coding research and has been published in the BMJ Open, the Journal of Law and Medicine and the Internal Medicine Journal and is a well-respected and sought-after speaker and author of information on health financing systems, both in Australia and overseas.

As an entrepreneur, Margaret is constantly seeking new ways to improve efficiencies in health administration, by leveraging technology to digitise outdated manual processes.

 

May 9, 2019
Private oncologists reject PM claims of ‘fee hikes’ for cancer patients
Enjoy all the benefits of membership
With a strong leadership group and a potential membership base of all private oncologists and haematologists, PCPA represents a critical group of specialists in the cancer care service spectrum.
behalf of Australian cancer patients and their families
The ‘Cancer Care, No Gaps’ Journey. Clinical trials – more patients, less cost.